The Prescription Drug User Fee Act (PDUFA VIII) represents the eighth iteration of the foundational U.S. regulatory framework, governing FDA user fee funding and drug review performance commitments for Fiscal Years 2028 through 2032.
Building on previous agreements between the FDA and the biopharmaceutical industry, PDUFA VIII aims to enhance predictable, science-based review processes while accelerating patient access to safe, innovative therapies. Key focus areas include modernizing premarket communications, refining Chemistry, Manufacturing, and Controls (CMC) facility oversight, expanding rare disease endpoint initiatives, and integrating digital health tools and AI into regulatory workflows to streamline drug development pipelines.
FDA has published its PDUFA VIII Notice of Public Meeting and Request for Comments on the Federal Register.
BIO Supports PDUFA VIII Commitment Letter and Urges Timely Reauthorization
August 13, 2026
Biotechnology Innovation Organization (BIO) Senior Vice President of Science & Regulatory Affairs Annetta Beauregard issued the following statement on the release of the Prescription Drug User Fee Act (PDUFA) VIII commitment letter:
“For more than 30 years, PDUFA has helped deliver hundreds of new medicines to American patients. As a lead industry negotiator for the PDUFA VIII agreement, BIO supports the PDUFA VIII commitment letter and its strengthening of regulatory review, advancing innovation, and helping deliver safe and effective treatments to patients.
“Specifically, the PDUFA VIII agreement includes important commitments that bolster the FDA’s core review activities, ensure accountability for predictable performance, improve financial sustainability and improve communication, transparency and efficiency.
“Timely, bipartisan reauthorization of PDUFA is vital for protecting the health of Americans, strengthening U.S. competitiveness, and maintaining America’s global leadership in medical innovation. BIO is committed to working with Congress to ensure reauthorization by September 30, 2027.”
The FDA has announced plans to hold a hybrid public meeting at 9am on 9/16 to discuss the proposed enhancements for the reauthorization of PDUFA for fiscal years (FYs) 2028 through 2033.
Learn More about PDUFA and the PDUFA VIII commitment letter HERE.